Pharmaceuticals analysts sizes up the data for Corcept Therapeutics (CORT)’ Relacorilant in ovarian cancer on an Analyst/Industry conference call to be held on July 10.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension
- Corcept Therapeutics Completes Key Study on Drug Interaction
- Corcept Therapeutics Explores Hypercortisolism in Hypertension: A Market Game Changer?
- Corcept Therapeutics’ Phase 2 Study Update: New Hope for Ovarian Cancer Treatment
- Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Resistant Hypertension